Red blood cell distribution width (RDW) has been recently demonstrated to be a predictor of inflammation. High pretreatment RDW level is associated with poor survival outcomes in various malignancies, although the results are controversial. We aimed to investigate the prognostic role of RDW. A systematic literature search was performed in MEDLINE and EMBASE till April 2018. Pooled hazard ratios (HRs) were estimated for overall survival (OS) and combined disease-free survival, progression-free survival, and recurrence-free survival (DFS/PFS/RFS). 49 studies with 19,790 individuals were included in the final analysis. High RDW level adversely affected both OS and DFS/PFS/RFS. For solid cancers, colorectal cancer (CRC) had the strongest relationship with poor OS, followed by hepatic cancer (HCC). Negative OS outcomes were also observed in hematological malignancies. Furthermore, patients at either early or advanced stage had inverse relationship between high pretreatment RDW and poor OS. Studies with cut-off values between 13% and 14% had worse HRs for OS and DFS/PFS/RFS than others. Furthermore, region under the curve (ROC) analysis was used widely to define cut-off values and had relatively closer relationship with poorer HRs. In conclusion, our results suggested that elevated pretreatment RDW level could be a negative predictor for cancer prognosis.
Glioma is the primary tumor with the highest incidence and the worst prognosis in the human central nervous system. Epithelial–mesenchymal transition (EMT) and immune responses are two crucial processes that contribute to it having the worst prognosis. However, a comprehensive correlation between these two processes remains elusive. The mRNA expression profiles and corresponding clinical data of patients with glioma were downloaded from public databases. EMT-related genes were collected and provided in the dbEMT database. Risk scores, Lasso regression, and enrichment analysis were conducted for functional validation. In our study, we used unsupervised clustering of EMT gene expression profiles to classify gliomas into two subtypes. We assessed the reliability of this classification system by testing it in three independent cohorts. Each subtype had different clinical and immune system characteristics. The study suggests a possible link between EMT and immune responses in gliomas.
Background: Niban‐like protein 2 (NIBAN2) has recently been linked to various neurological diseases; however, its exact role in glioma development remains unclear. Methods: Quantitative reverse transcription–polymerase chain reaction, western blotting, and immunohistochemistry were used to evaluate NIBAN2 expression in glioma tissues. In addition, we examined the effects of NIBAN2 on glioma progression in various functional trials. Animal models were used to clarify the role of NIBAN2, especially its impact on the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. Results: The research outcomes revealed that NIBAN2 was highly upregulated in gliomas and its levels were strongly correlated with tumor grade and clinical outcomes. Functional assays showed that NIBAN2 enhanced glioma cell aggressiveness by activating JAK2/STAT3 signaling and promoted tumor growth by preventing apoptosis and accelerating the cell cycle. Conclusion: The findings of this study show that NIBAN2 plays a key role in glioma aggression and poor prognosis, suggesting that it is a potential therapeutic target.
SKP2 (S-phase kinase-associated protein 2) plays an important role in the regulation of the cell cycle, tumorigenesis, progression, and metastasis. However, its functional role in gliomas is currently unclear. This study aimed to investigate the relationship between SKP2 and the progression of gliomas, and its effects on the glioma cell cycle. The relationship between SKP2 expression levels and clinical characteristics of gliomas was explored in our datasets. Kaplan–Meier analysis and COX regression were conducted to evaluate the prognostic role of SKP2. Differentially expressed genes were identified between high and low SKP2 groups. The function and related mechanisms of SKP2 were evaluated based on Gene Ontology and Gene Set Enrichment Analysis. LASSO-Cox was used to screen the variables, and the prediction model was established by nomogram analysis. The effects of SKP2 on the glioma cell cycle were examined in cellular experiments. The SKP2 expression level was positively correlated with adverse clinical features of gliomas, and overall survival with high SKP2 expression was significantly shortened. Gene enrichment analysis showed that the differential genes in the SKP2 high-expression group were mainly enriched in cell cycle and mitosis. In vitro experiments confirmed that silencing of SKP2 arrested the glioma cell cycle at the G1 phase in both U87 and U251 cells. In conclusion, SKP2 may serve as a potential prognostic biomarker for glioma patients and is associated with poor prognosis. Additionally, SKP2 is closely related to the glioma cell cycle, suggesting that SKP2 may serve as a potential therapeutic target. However, further prospective studies and external cohort validations are needed to confirm its clinical applicability.
Objective . Sources of epileptic traveling waves offer critical insights into seizure onset zone (SOZ) localization, making them invaluable for preoperative assessment in patients with epilepsy. However, the absence of tailored source-tracing methods and the inherent instability of epileptiform activity make it difficult to achieve reliable source identification for SOZ localization. This study aimed to analyze the propagation pattern during seizure events and develop a framework to trace the sources of epileptic expanding traveling waves (ETWs). Approach . 101 seizure events were recorded from five 4-Aminopyridine-induced acute cortical rat epilepsy models. In each seizure event, epileptiform activities were classified into two categories according to their time-frequency diagrams (multiband and non-multiband epileptiform activities). The center of the SOZ was regarded as the recording site with the largest amplitude of epileptiform activities. Using the spatial-phase-based analysis, we analyzed the propagation pattern during the seizure event and extracted the ETWs. The sources of ETWs were traced by the intersection of spatial-phase-gradient. Main results . The ETW proportion of multiband epileptiform activities was 62.7% 8.3%, significantly higher than those in non-multiband epileptiform activities (53.8% 9.0%). ETWs with stable propagation patterns gave rise to a concentrated source tracing outcome. The single-band signal (component of the multiband activities) had a more stable ETW propagation pattern than both the multiband and non-multiband activities. The source tracing results of the single-band signals clustered around the SOZ center and remained stable even when the SOZ center was out of coverage (removing half of the recording sites, among which the SOZ center was included). Significance . The proposed framework enables ETW extraction from epileptiform activities and can trace ETW sources even when the sources are out of coverage. Therefore, the proposed framework may prove clinically valuable in cases with sparse intracranial recordings, addressing the limitation of traditional SOZ localization methods.
Background: Thalamic gliomas (TGs) remain a formidable clinical challenge for accurate diagnosis and effective therapy. This study aims to refine molecular diagnosis and surgical management of TGs by integrating clinicopathological and multi-omics data. Methods: We analyzed 106 TGs, comprising 65 diffuse midline glioma (DMG) and 41 non-DMG, using genomic profiling, single-cell RNA sequencing, and orthogonal assays. Surgical outcomes were evaluated using rigorous causal inference frameworks, including propensity score matching and difference-in-differences analyses. Results: Genomic profiling revealed striking mutual exclusivity between H3F3A mutations and CDKN2A/B (9p21) loss. Single-cell and orthogonal assays validated that 9p21 loss emerged as a highly specific adjunctive marker favoring non-DMG over DMG. Causal inference analyses consistently demonstrated that microsurgical third ventriculostomy (mTV) confers profound protection against postoperative hydrocephalus (risk reduction > 60%). Multivariate analysis identified the transfrontal approach as an independent predictor of postoperative motor deficits. Survival analysis showed that the median overall survival of this cohort following surgical resection was 21.0 months. Extent of resection and tumor mutational burden emerged as the principal independent determinants of prognosis, whereas postoperative KPS showed survival stratification in univariable/subgroup analyses but was not independently significant in multivariable model. Conclusions: In this 106-patient cohort study, we delineated the somatic mutational landscape of thalamic glioma and showed that 9p21 loss is mutually exclusive with H3F3A mutations, providing a highly specific adjunctive marker for thalamic glioma. We further demonstrated that maximal surgical resection confers a survival benefit and intraoperative mTV serves as a standardized treatment workflow to optimize care for thalamic glioma.